Filed by newsfilecorp.com Lexaria Studies Nitric Oxide Levels in Human Subjects Kelowna, BC /

Lexaria Studies Nitric Oxide Levels in Human Subjects

Kelowna, BC / January 13, 2016 / Lexaria, Corp. (OTCQB:LXRP)

(CSE:LXX) (the Company ) is pleased to announce it has commissioned a study of

nitric oxide levels in humans, as a biomarker for absorption of cannabidiol. The

study is expected to provide additional evidence of the efficient absorption of

cannabidiol from Lexaria food products enhanced with hemp oil, by demonstrating

the elevation of nitric oxide in the human body in response to product

The 1998 Nobel Prize in Medicine was awarded to Dr. Louis

Ignarro, Robert F. Furchgott and Ferid Murad for their discovery that nitric

oxide is a signaling molecule responsible for dilation of blood vessels. In the

heart, nitric oxide is the body s way of protecting against cardiovascular

disease, Ignarro said. The arteries make nitric oxide to lower blood pressure

and improve blood flow to organs because it is a vaso-dialator, which means it

widens or relaxes the arteries so that more blood can flow through, therefore

lowering the pressure within the arterial system. (www.news.usc.edu)

Nitric oxide levels in the body can be elevated through a

variety of dietary sources including some of the ingredients found in Lexaria

and ViPova food products. An increase in nitrate intake can augment circulating

nitrite and nitric oxide. Consumption of a nitrate-rich meal can lower systolic

blood pressure and pulse pressure and increase large artery compliance acutely

in healthy men and women. If sustained, these effects could contribute to better

cardiovascular health. (1) Lexaria believes that elevated nitric oxide levels

after the ingestion of Lexaria food products could be of great interest to the

health & wellness and fitness communities.

Another potent promoter of nitric oxide levels in the human

body is the endocannabinoid anandamide, which is augmented significantly through

administration of products that deliver bioavailable cannabidiol. In light of

this fact, Lexaria has set out to demonstrate that its cannabinoid bioabsorption

enhancing technology can augment nitric oxide levels in significant quantities.

The study is testing the effects of nitric oxide levels following ingestion of

several flavors of ViPova Tea, ViPova Coffee and Hot Chocolate, as well as

both flavors of Lexaria Energy Foods protein-energy bars. Lexaria is

specifically quantifying nitric oxide response secreted via the salivary

Beyond serving as a biomarker surrogate for cannabidiol

absorption, it is important to note that nitric oxide levels within the human

body have important implications for overall health and wellness. Elevated

levels of nitric oxide in the body have been shown to have many benefits ranging

from anti-infective properties to athletic performance and endurance enhancing

effects. Nitric oxide causes increased flow of oxygen and nutrients to tissues

and simultaneous increased removal of toxins from tissues such as lactic acid

which accumulates due to intense physical activity. Its half-life is measured

only in seconds, meaning it must be produced by the body on a regular basis in

order to be available for use.

Dietary nitrate supplementation improved endurance during

severe-intensity exercise in recreationally active subjects. (2) Therefore,

Lexaria s study findings could have numerous health applications associated with

stimulation of nitric oxide production in the human body due to the cannabidiol

absorption enhancing properties of its technology, in addition to the other

medicinal effects of cannabinoid administration in general.

Lexaria expects to conclude analysis and reporting of its study

findings shortly and will announce the outcome soon.

Nitric Oxide is a different molecule from Nitrous Oxide or from

Nitrogen Dioxide and should not be confused with either of them. Nitric Oxide is

naturally produced by most animals, including humans.

Lexaria is a food sciences company focused on

the delivery of active compounds that can behave as superfoods through its

proprietary infusion technologies. Lexaria s technology enables higher

bioavailability rates for CBD; THC; NSAIDs; Nicotine and other molecules than is

possible without lipophilic enhancement technology. This can allow for lower

overall dosing requirements and/or higher effectiveness in active molecule

delivery. Lexaria hopes to reduce other common but less healthy ingestion

methods such as smoking as it embraces the benefits of public health.

legal hemp oil extracts, grown from agricultural hemp in locations where it is

legal to do so, in ViPovaTM-branded tea. ViPovaTM uses its

patent-pending process to infuse concentrated amounts of hemp oil within lipids

in its tea, providing more bioactivity and comfort to the body during the

absorption process. Only ViPovaTM has this ground-breaking technology

for hemp oil/lipid infusion. www.vipova.com

FOR FURTHER INFORMATION PLEASE CONTACT:

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements

which are not historical facts are forward-looking statements. The Company makes

forward-looking public statements concerning its expected future financial

position, results of operations, cash flows, financing plans, business strategy,

products and services, competitive positions, growth opportunities, plans and

objectives of management for future operations, including statements that

include words such as "anticipate," "if," "believe," "plan," "estimate,"

"expect," "intend," "may," "could," "should," "will," and other similar

expressions are forward-looking statements, including but not limited to: the

potential industry-changing achievement as a results of the laboratory test

findings, that the in vitro findings provide compelling evidence of the

future intestinal absorption enhancing capabilities of the technology, that the

Company may become a leader in the development of potentially a wide range of

product lines with enhanced gastro-intestinal absorption performance

capabilities, that bioavailability testing in animals is likely to yield even

stronger absorption results in the presence of natural intestinal fluid

conditions, or that the technology will function in a similar manner if tested

with THC, nicotine, or any of the other molecules named in our patent

applications. Such forward-looking statements are estimates reflecting the

Company's best judgment based upon current information and involve a number of

risks and uncertainties, and there can be no assurance that other factors will

not affect the accuracy of such forward-looking statements. Access to capital,

or lack thereof, is a major risk and there is no assurance that the Company will

be able to raise required working capital. Factors which could cause actual

results to differ materially from those estimated by the Company include, but

are not limited to, government regulation, managing and maintaining growth, the

effect of adverse publicity, litigation, competition, the patent application and

approval process and other factors which may be identified from time to time in